ReviewSeminars in respiratory and critical care medicine2015
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.
Review in Seminars in respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Using different methods to process forced expiratory volume in one second (FEVF1000Research · 2018Trial
- Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report.Clinical case reports · 2026Article
- Review
- Article
- Resolution of acute rejection in a bilateral double-lung transplanted cystic fibrosis patient following phage intervention.ASM case reports · 2025Article
- Airway associated inflammation in post-transplant cystic fibrosis patients as a predictor of chronic lung allograft dysfunction (CLAD).Journal of clinical pathology · 2025Observational
- Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis.Clinical kidney journal · 2024Article
- Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review.Cureus · 2024Review
- Metabolic complications in lung transplantation for cystic fibrosis - A case control study.Heliyon · 2024Article
- Lung Transplantation in a New Era in the Field of Cystic Fibrosis.Life (Basel, Switzerland) · 2023Review
- Pre-Lung transplant reflux testing demonstrates high prevalence of gastroesophageal reflux in cystic fibrosis and reduces chronic rejection risk.World journal of transplantation · 2023Article
- A case of localized paranasal sinusitis associated withHeliyon · 2023Article
- Review
- A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning-Based Risk Prediction Models.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis.Journal of clinical & translational endocrinology · 2022Article
- Successful non-surgical treatment of pseudomonas choroidal abscess in cystic fibrosis with previous double lung transplantation.BMJ case reports · 2022Article
- Outcome of lung transplantation in cystic fibrosis patients with severe asymmetric chest cavities.JTCVS open · 2021Article
- Genetic diversification of persistentVirulence · 2021Article
- Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients.Journal of clinical microbiology · 2021Article
- Host-Pathogen Interactions after Lung Transplant: Are Cystic Fibrosis Patients Unique?Cell reports. Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Survival in patients with cystic fibrosis (CF) has improved dramatically over the past 30 to 40 years, with mean survival now approximately 40 years. Nonetheless, progressive respiratory insufficiency remains the major cause of mortality in CF patients, and lung transplantation (LT) is eventually required. Timing of listing for LT is critical, because up to 25 to 41% of CF patients have died while awaiting LT. Globally, approximately 16.4% of lung transplants are performed in adults with CF. Survival rates for LT recipients with CF are superior to other indications, yet LT is associated with substantial morbidity and mortality (∼50% at 5-year survival rates). Myriad complications of LT include allograft failure (acute or chronic), opportunistic infections, and complications of chronic immunosuppressive medications (including malignancy). Determining which patients are candidates for LT is difficult, and survival benefit remains uncertain. In this review, we discuss when LT should be considered, criteria for identifying candidates, contraindications to LT, results post-LT, and specific complications that may be associated with LT. Infectious complications that may complicate CF (particularly Burkholderia cepacia spp., opportunistic fungi, and nontuberculous mycobacteria) are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.